Twist Bioscience Corporat... (TWST)
| Bid | 38.5 |
| Market Cap | 2.38B |
| Revenue (ttm) | 330.19M |
| Net Income (ttm) | -197.31M |
| EPS (ttm) | -3.38 |
| PE Ratio (ttm) | -11.8 |
| Forward PE | -25.49 |
| Analyst | Buy |
| Ask | 40 |
| Volume | 787,817 |
| Avg. Volume (20D) | 1,126,036 |
| Open | 39.76 |
| Previous Close | 38.85 |
| Day's Range | 38.56 - 40.34 |
| 52-Week Range | 27.41 - 60.90 |
| Beta | 2.34 |
About TWST
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration ...
Analyst Forecast
According to 9 analyst ratings, the average rating for TWST stock is "Buy." The 12-month stock price forecast is $56, which is an increase of 40.35% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Twist Bioscience Corporation (TWST) Q1 2025 Earnings Call TranscriptTwist Bioscience Corporation (NASDAQ:TWST ) Q1 2025 Earnings Conference Call February 3, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust...
2 months ago · businesswire.com
Twist Bioscience Announces Fiscal 2025 First Quarter Financial ResultsSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...